Common TitleC-204
Official Title A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of Rilpivirine (TMC278) in Antiretroviral-Naive HIV-1 Infected Subjects
Phase Phase IIB
ClinicalTrials.gov NCT00110305
Treatments
Rilpivirine
Rilpivirine
Tradename:EdurantOther Names:RPVClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)Categories PharmacologyTreatment-NaiveAdverse Effects
Funding
IndustryTibotec Pharmaceuticals, Ireland
References
- Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55-65.
- Wilkin A, Pozniak AL, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012;28:437-46.